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Efficient	siRNA-peptide	conjugation	for	specific	targeted	delivery	
to	tumor	cells		
Albert	Gandioso,a	Anna	Massaguer,b	Núria	Villegas,cd	Cándida	Salvans,c	Dani	Sánchez,c	Isabelle	
Brun-Heath,c	Vicente	Marchán,*a	Modesto	Orozcocde	and	Montserrat	Terrazas*c	
Despite	 the	 broad	 applicability	 of	 the	 Huisgen	 cycloaddition	
reaction,	the	click	functionalization	of	RNAs	with	peptides	remains	
still	 a	 challenge.	 Here	we	 describe	 a	 straightforward	method	 for	
the	click	functionalization	of	siRNAs	with	peptides	of	different	size	
and	complexity.	Among	them,	a	promising	peptide	carrier	for	the	
selective	siRNA	delivery	into	HER2+	breast	cancer	cell	lines.		
RNA	 interference	 (RNAi)1	 is	 a	 potent	 gene	 regulatory	process	
triggered	 by	 21-nt	 RNA	duplexes	 (siRNAs)2	 that	 has	 attracted	
much	 attention	 both	 for	 biotechnological	 and	 biomedical	
points	 of	 view.	 Unfortunately,	 the	 poor	 ability	 of	 siRNAs	 to	
cross	 cell	membranes	dramatically	 limits	 their	practical	use.1b	
To	 overcome	 this	 limitation,	much	 effort	 has	 been	dedicated	
to	 develop	 general	 delivery	 vehicles3	 involving	 positively	
charged	peptides,3c	 lipids,3de	dendrimers	and	nanocarriers3f	as	
well	as	receptor-mediated	delivery	approaches.3g	This	research	
has	 produced	 a	 great	 variety	 of	 modified	 siRNAs3	 that	 have	
contributed	 to	progress	 in	 this	area.	For	example,	 in	a	 recent	
work,3h	 functionalization	 of	 siRNAs	 at	 the	 3'-termini	 of	 both	
strands	with	the	cell	permeable	peptide	KALLAL	has	allowed	to	
improve	 the	 combination	 of	 siRNA	 and	 cationic	 vectors,	
increasing	 the	 half-life	 of	 siRNAs	 and	 their	 release	 from	 the	
endosome.	 On	 the	 other	 hand,	 receptor	 mediated	 delivery	
approaches	 are	 particularly	 interesting	 since	 they	 involve	
linking	 the	siRNA	 to	a	 targeting	 ligand	 (e.g.	 folate	or	peptide)	
that	 binds	 a	 membrane	 receptor	 expressed	 in	 a	 specific	 cell	
line.	 Unfortunately,	 despite	 the	 potential	 of	 siRNA-peptide	
conjugates,	 their	 preparation	 can	 be	 troublesome.	 For	
example,	 solid-phase	 step-wise	 synthesis	 can	 present	
problems	of	 functional	group	 incompatibility.3a	An	alternative	
consists	in	synthesizing	separately	RNA	and	peptide	fragments	
functionalized	 with	 potentially	 reactive	 groups,	 and	 then	 to	
chemoselectively	 react	 (post-synthetically)	 both	 fragments	 in	
solution.3a	 Among	 various	 oligonucleotide	 linking	 strategies	
developed	 to	 date,	 the	 copper(I)-catalyzed	 azide-alkyne	
cycloaddition	(CuAAC,	“click”)4	is	one	of	the	most	selective	and	
versatile.5	This	approach	has	produced	a	large	number	of	DNAs	
functionalized	 with	 fluorescent	 probes,6ab	 lipids6c	 and	 other	
carriers.6d	Although	 fewer	 in	number,	 several	DNA-,	 2’-O-Me-
RNA-	 and	 locked	 nucleic	 acid-peptide	 conjugates	 have	 also	
been	 synthesized.7,3c	However,	 due	 to	 the	 inherent	 lability	 of	
RNA	 (with	 free	 2’-OH)	 limited	 research	 has	 been	 devoted	 to	
RNA	 click	 conjugation.8	 Most	 of	 the	 examples	 have	 been	
focused	 on	 the	 conjugation	 of	 small	 molecules3e,8a-c	 and	
fluorescent	 labels.8de	To	the	best	of	our	knowledge,	there	are	
only	 two	 examples	 of	 click	 post-conjugation	 of	 RNA	 to	 small	
peptides,8fg	 both	 of	 them	 implying	 long	 reaction	 times,	 large	
excesses	 of	 the	 peptides	 and	 several	 synthetic	 steps	 for	 the	
incorporation	 of	 the	 azide	 to	 the	 RNA.	Most	 of	 the	methods	
that	have	been	used	to	 functionalize	RNA	with	peptides	have	
been	 restricted	 to	 RNAs	 modified	 with	 thiol9a	 or	 amino9b,3a	
groups,	 which	 are	 reacted	 with	 maleimide	 or	 N-
hydroxysuccinimide	 (NHS)	esters.	However,	although	the	NHS	
approach	is	more	efficient	than	the	maleimide-thiol	reaction,	it		
	 		
	
	
	
	
	
	
	
	
	
	
Fig.	1	siRNA-peptide	conjugates	used	in	this	study.	
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cannot	be	performed	in	the	presence	of	free	amino	groups	and	
requires	 slightly	 alkaline	 pH.	 Therefore,	 expanding	 the	 use	 of	
click	 chemistry	 to	 the	 conjugation	 of	 peptides	 to	 RNA	would	
represent	 a	 great	 improvement	 in	 the	 synthesis	 and	
applications	of	RNA-peptide	conjugates.	
	 Here	we	present	an	efficient	method	for	the	Huisgen-based	
click	 functionalization	 of	 siRNAs	 with	 peptides	 targeting	
relevant	receptors	 frequently	overexpressed	 in	major	tumors:	
integrins,	somatostatin	and	HER2	receptors	(Fig.	1).	
	 It	 is	 well-known	 that	 some	 integrins	 (specially,	 the	 αVβ3	
subfamily)	 recognize	 the	 tripeptide	 motif	 RGD	 with	 high	
affinity	and	selectivity,10	offering	 the	possibility	of	using	RGD-
containing	 peptides	 to	 deliver	 drugs	 into	 specific	 cancer	 cell	
types	overexpressing	them.	Another	candidate	for	tumor-drug	
delivery	 is	 octreotide,11a	 a	 potent	 FDA-approved	 synthetic	
cyclooctapeptide	 agonist	 of	 the	 endocrine	 hormone	
somatostatin	 that	 displays	 high	 affinity	 for	 the	 somatostatin	
subtype-2	 receptor	 (SSTR2),	which	 is	 very	 prevalent	 in	 tumor	
cells.11b	On	the	other	hand,	several	attempts	to	overcome	the	
limitations	 associated	 with	 antibody-based	 anti-HER2	
therapies12a	 have	 led	 to	 the	 development	 of	 several	 small	
antigen-mimetic	 peptides	 of	 great	 therapeutic	 potential.12bc	
Among	 them,	 a	 peptide	 carrier	 based	 on	 a	 cyclic	 anti-HER2	
peptide	 (AHNP)	 linked	 to	 a	 Tat	 cell-penetrating	 peptide	 (Tat-
AHNP,	Fig.	1)	has	been	reported	to	enter	HER2+	breast	cancer	
cells	 with	 high	 efficiency.12b	 Unfortunately,	 there	 are	 no	
examples	in	the	literature	of	the	conjugation	of	vehicles	based	
on	 this	 peptide	 to	 siRNAs.	With	 the	 aim	 of	 targeting	 siRNAs	
directly	to	specific	tumor	cells	overexpressing	these	receptors,	
we	have	explored	the	click	functionalization	of	siRNAs	with	the	
cyclic	 RGD-containing	 cyclopentapeptide	 c(RGDfK),	 octreotide	
and	the	promising	Tat-AHNP	peptide	carrier.		
	 Because	 siRNAs	modified	 at	 the	 ends	 of	 the	 sense	 strand	
are	 better	 tolerated	 by	 the	 RNAi	 machinery,	 we	 studied	 the	
CuAAC	 click	 reaction	 between	 a	 5’-alkynyl-modified	 sense	
siRNA	 strand	 targeting	 the	 endogenous	 gene	HER2	 (1;	 Fig.	 2)	
and	 azido-bearing	 peptides	 a-c.	 To	 achieve	 the	 RNA	 5’-end	
conjugation,	 a	 deoxyuridine	 phosphoramidite	 with	 an	
octadiyne	handle	at	C5	(5oU)	was	used	during	RNA	synthesis.			
Fig.	 2	 Sequences	 of	 5’-alkynyl-sense	 RNA	 and	 guide	 RNA	
strands,	 azido	 peptides	 and	 siRNA-peptide	 click	 conjugates	
targeting	the	endogenous	gene	HER2,	and	Tm	data.	
	 Following	 previous	 approaches,8e	 we	 selected	 CuSO4	 and	
sodium	 ascorbate	 to	 carry	 out	 RNA-peptide	 conjugations,	
which	were	followed	by	HPLC	and	PAGE	(Fig.	3	and	Fig.	S2-S4,	
ESI).	We	first	studied	the	reaction	between	RNA	1	 (0.15	μmol	
RNA;	1mM)	and	a	two-fold	excess	of	the	RGD-containing	azido	
peptide	 a	 (Fig.	 S1)	 in	 the	 presence	 of	 CuSO4	 (15	 mM)	 and	
sodium	 ascorbate	 (15	 mM)	 in	 a	 Tris·HCl-ACN	 (8:2	 mixture).	
HPLC	 analysis	 of	 the	 reaction	 after	 30	 min	 revealed	 the	
formation	 of	 a	 new	 peak	 corresponding	 to	 the	 desired	
conjugate	 (2;	 as	 determined	 by	 MS	 analysis	 of	 the	 isolated	
peak),	although	conversion	was	 far	 from	being	complete	 (Fig.	
S2,	 ESI).	When	 larger	 excess	 of	 CuSO4	 and	 sodium	 ascorbate	
(45	equivalents;	added	in	three	separate	additions)	were	used,	
conversion	 was	 quantitative	 within	 90	 min	 and	 conjugate	 2	
was	obtained	as	a	single	product	(as	determined	by	HPLC	and	
PAGE	analyses	of	the	reaction;	Fig.	S2-S4,	ESI)	 in	40%	isolated	
yield.	By	using	these	conditions,	the	larger	and	more	complex	
octreotide	 and	 Tat-AHNP-azido	 peptides	 b	 and	 c	 (containing	
cysteine	 bridges	 and	 several	 trifunctional	 amino	 acids,	
including	 Lys;	 Fig.	 S1)	 were	 subsequently	 clicked	 very	
efficiently	 to	 the	RNA	1,	 to	 give	 conjugates	3	and	4	 as	 single	
products	 (Fig.	 3,	 Fig.	 S3-S4,	 ESI)	 (45%	and	35%	 isolated	 yield,	
respectively).	 It	 is	 worth	 noting	 that	 complete	 conversion	 to	
the	 final	 product	was	 observed	 in	 the	 three	 cases	 under	 the	
optimized	 conditions,	 and	 the	 three	 RNA-peptide	 conjugates	
were	isolated	with	excellent	purity	using	reversed-phase	semi-
preparative	HPLC	and	 characterized	by	MALDI-TOF	MS	 (Table	
S1).	Importantly,	analysis	of	the	purified	conjugates	by	ICP-MS	
(ESI)	 revealed	 that	 copper	 contamination	 from	 CuAAC	 click	
reaction	 was	 negligible	 [10-25	 ppb	 of	 copper	 for	 a	 750	 nM	
siRNA-peptide	 dose,	 see	 below,	 which	 is	 considerably	 below	
the	average	content	of	copper	in	human	serum	(1-2	ppm)].	
	 Incorporation	 of	 c(RGDfK),	 octreotide	 or	 Tat-AHNP	 to	 the	
5’-end	 of	 the	 siRNA	 did	 not	 cause	 negative	 effects	 on	 the	
stability	 of	 the	 double-helix	 (Fig.	 2	 and	 Fig.	 S5).	 Indeed,	
thermal	 denaturation	 studies	with	 siRNA	duplexes	 formed	by	
5’-peptidyl	modified	sequences	2-4	paired	with	the	unmodified	
guide	 sequence	5	 (siRNAs	 I-III)	 revealed	melting	 temperature	
values	 very	 similar	 to	 that	 of	 the	 corresponding	 unmodified	
siRNA	IV	(formed	by	unmodified	RNAs	5	and	6).		
	 To	 investigate	 the	 ability	 of	 siRNA-peptide	 conjugates	 I-III	
to	selectively	enter	into	cancer	cells	and	induce	RNAi-mediated	
inhibition	of	gene	expression,	we	first	focused	on	studying	the	
level	of	expression	of	αVβ3	integrin,	SSTR2	and	HER2	receptors	
in	a	panel	of	 tumor	 cell	 lines.	 The	 receptor’s	expression	 level	
on	the	cell	surface	was	characterized	by	flow	cytometry	using		
Fig.	 3	 (A,	 B)	 Reversed-phase	 HPLC	 analysis	 of	 sense-siRNA	
conjugate	 3.	 Panel	 A:	 reaction	 crude;	 panel	 B:	 fully	 purified	
conjugate.	(C)	Denaturing	PAGE	of	the	reaction	of	formation	of	
conjugate	3	(lane	1:	5'-alkynyl	RNA	1,	lane	2:	mixture	of	RNA	1	
and	the	reaction	crude;	lane	3:	reaction	crude).	
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specific	antibodies	(Fig.	S6).	We	found	that	SK-BR-3	and	BT-474	
breast	 cancer	 cells	 expressed	 high	 levels	 of	 HER2	 (mean	
fluorescence	 intensity	 of	 1166.6	 and	 1302.2,	 respectively),	
which	 is	 in	 good	 agreement	with	 data	 from	 the	 literature.12b	
Interestingly,	the	HER2+	SK-BR-3	cell	line	also	expressed	SSTR2	
(mean	 fluorescence	 intensity	 of	 52.1),	 which	 could	 be	
exploited	 to	 facilitate	 the	 internalization	 of	 siRNA-octreotide	
conjugate.	 However,	 we	 detected	 very	 low	 levels	 of	 αVβ3	
integrin	 expression	 in	 this	 cell	 line	 (mean	 fluorescence	
intensity	 of	 11.8).	 In	 contrast,	 SK-MEL-28	 melanoma	 cells	
express	 high	 levels	 of	 αVβ3	 integrin	 (mean	 fluorescence	
intensity	 of	 278.9)	 and	 acceptable	 levels	 of	 HER2	 (mean	
fluorescence	 intensity	 of	 36.9).	 As	 expected,	 flow	 cytometry	
studies	with	 FITC-labelled	peptides	 confirmed	 that	 octreotide	
and	Tat-AHNP	were	able	to	enter	the	SK-BR-3	cell	line	(Fig.	S7).	
Satisfactory	 results	 were	 also	 obtained	 with	 FITC-c(RGDfK)	
peptide	 in	 SK-MEL-28	 cells.13	 Identical	 results	 were	 obtained	
after	exposing	the	peptides	to	siRNA	annealing	conditions	(Fig.	
S7),	 suggesting	 that	 the	 active	 peptide	 structure	 responsible	
for	interaction	with	the	receptor	remains	unaffected	after	the	
annealing	process	required	in	inhibition	studies	(see	below).	
	 The	overall	data	suggest	that	the	breast	cancer	cell	line	SK-
BR-3	is	a	good	model	to	evaluate	the	biological	activity	of	Tat-
AHNP	 and	 octreotide-containing	 siRNA	 conjugates	 targeting	
the	HER2	mRNA,	while	the	SK-MEL-28	cell	 line	can	be	used	to	
test	 the	 c(RGDfK)-siRNA	 conjugate.	 Due	 to	 the	 significant	
relevance	 of	 the	 Tat-AHNP	 peptide	 carrier,	 we	 also	 used	 the	
HER2+	 breast	 cancer	 cell	 line	 BT-474	 to	 validate	 this	 system.	
The	 non-malignant	 HEK-293	 cell	 line	 was	 used	 as	 negative	
control	for	Tat-AHNP-containing	siRNA	conjugates,	as	the	level	
of	HER2	expression	is	almost	negligible	in	this	cell	line	(Fig.	S8,	
ESI).		
	 We	next	studied	the	ability	of	siRNA-peptide	conjugates	to	
silence	an	endogenous	gene	(HER2)	into	the	selected	cell	lines.	
With	this	aim,	we	hybridized	the	c(RGDfK),	octreotide-	and	Tat-
AHNP-sense	 strands	 (2,	 3	 and	 4,	 respectively)	 to	 the	
complementary	 unmodified	 guide	 strand	 5	 (Fig.	 2)	 to	 give	
siRNA-peptide	 conjugates	 I-III,	 respectively.	 To	 investigate	 if	
the	 presence	 of	 c(RGDfK),	 octreotide	 and	 Tat-AHNP	 peptides	
at	 the	 5'-end	 of	 the	 sense	 strand	was	 tolerated	 by	 the	 RNAi	
machinery,	we	carried	out	a	 first	series	of	RNAi	studies	 in	SK-
BR-3	 and	 SK-MEL-28	 cells	 in	 the	 presence	 of	 the	 commercial	
transfecting	 agent	 Lipofectamine	 2000.	 As	 a	 positive	 control	
we	used	the	unmodified	siRNA	analogue	 IV.	The	effect	of	 the	
siRNAs	on	HER2	protein	levels	was	assessed	by	western	blot	48	
h	after	transfection.	Dose-response	experiments	revealed	that	
all	 siRNA-peptide	 conjugates	 (I-III)	 are	 well	 tolerated	 by	 the	
RNAi	 machinery,	 displaying	 a	 dose-dependent	 profile	
comparable	to	that	of	the	unmodified	siRNA	(IV)	 (Fig.	4,	A-C).	
	 Encouraged	by	 these	observations,	we	next	examined	 the	
ability	 of	 the	 siRNA-peptide	 conjugates	 to	 impart	 the	desired	
RNAi	 effect	 in	 the	 selected	 cell	 lines	 in	 the	 absence	 of	
transfecting	agent.	Initial	control	experiments	with	unmodified	
siRNA	 IV	 in	SK-BR-3	and	SK-MEL-28	cell	 lines	showed	that	the	
HER2	expression	was	not	affected	(Fig.	4,	D	and	E).	In	contrast,	
we	observed	a	significant	HER2	knockdown	in	the	presence	of	
the	 octreotide-siRNA	 conjugate	 (II)	 in	 the	 SK-BR-3	 cell	 lines	
(45%	 gene	 knockdown	 at	 750	 nM	 concentration;	 Fig.	 4F).	
Encouraging	results	were	also	obtained	for	the	Tat-AHNP-	and	
cRGDfk-siRNA	conjugates	(III	and	I)	in	SK-BR-3	and	SK-MEL-28		
cells,	 respectively	 (28%	gene	knockdown	 for	 siRNA	 III	 at	1μM	
concentration	 and	 27%	 gene	 knockdown	 for	 siRNA	 I	 at	 2μM	
concentration;	Fig.	4,	G	and	H),	proving	uptake	and	activation	
of	 the	 RNAi	machinery.	 Given	 the	 great	 potential	 of	 the	 Tat-
AHNP	 carrier	 in	 the	 selective	 treatment	 of	HER2+	 cancer,	we	
next	 proceeded	 to	 investigate	 the	 inhibitory	 activity	 of	 Tat-
AHNP-siRNA	 conjugate	 III	 in	 another	 relevant	 HER2+	 cancer	
cell	line:	BT-474.	Very	interestingly,	inhibitory	activity	was	also	
observed	 in	 this	 cell	 line	 in	 the	absence	of	 transfecting	agent	
(30%	gene	knockdown	at	750	nM	siRNA	III	concentration;	Fig.	
4	 I).	To	 further	confirm	that	 the	 inhibitory	activity	of	 the	Tat-
AHNP	 bearing	 conjugate	was	 a	 consequence	 of	 selective	 cell	
uptake,	 we	 next	 treated	 a	 non-malignant	 cell	 line	 expressing	
very	 low	 levels	 of	 HER2	 (HEK-293)	 with	 a	 Tat-AHNP-bearing	
siRNA	 targeting	 the	 Renilla	 mRNA	 (Fig	 5,	 A-C).	 To	 carry	 out	
these	experiments,	we	conjugated	the	Tat-AHNP	carrier	to	the	
5'-end	 of	 the	 sense	 strand	 of	 a	 siRNA	 targeting	 the	 Renilla	
luciferase	 gene	 (RNA	7;	 Fig.	 5A).	 After	 hybridization	with	 the	
unmodified	complementary	guide	RNA	strand	(8),	the	resulting	
Tat-AHNP	 siRNA	 conjugate	 (V)	 was	 used	 to	 study	 the	Renilla	
gene	knockdown	 in	HEK-293	 cells	previously	 transfected	with	
Renilla	 and	 Firefly	 luciferase	 plasmids.	 A	 first	 series	 of	
experiments	performed	 in	 the	presence	of	 transfecting	agent	
(Fig.	5B)	confirmed	that	Tat-AHNP	Renilla-siRNA	conjugate	was	
able	 to	 activate	 the	 RNAi	 machinery	 in	 this	 cell	 line,	 with	
activities	comparable	to	that	of	the	corresponding	unmodified	
siRNA	 analogue	 (VI)	 (96%	 inhibition	 of	 Renilla	 expression	 in	
both	 cases,	 at	 90	 nM	 siRNA	 concentration).	 In	 contrast,	 the	
levels	 of	 Renilla	 luciferase	 in	 this	 cell	 line	 were	 not	 affected	
after	 treatment	 with	 both	 siRNAs	 in	 the	 absence	 of	
transfecting	agent	(Figure	5C).	These	results	confirm	that	the	
Tat-AHNP	 carrier	 displays	 the	 internalization	 properties	
required	 to	 deliver	 siRNAs	 into	 HER2	 overexpressing	 cancer	
cell	lines	in	a	selective	manner.	
Fig.	 4	 Western	 blot	 analysis	 of	 cells	 treated	 with	 siRNA	
analogues	 in	 the	 presence	 (A-C)	 and	 in	 the	 absence	 of	
transfecting	 agent	 (D-I).	 Panels	 A,	 D,	 F	 and	 G:	 SK-BR-3	 cells;	
Panels	B,	C,	E	and	H:	SK-MEL-28	cells;	panel	I:	BT-474	cells.	β-
actin	was	used	as	loading	control.	Untreated	cells:	cells	treated	
with	cell	medium	alone.	
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Fig.	 5	 (A)	 Sequences	 of	 5'-Tat-AHNP-siRNA	 conjugate	 V	 and	
unmodified	 siRNA	VI	 targeting	 the	Renilla	 luciferase	gene.	 (B,	
C)	RNAi	assays	with	siRNAs	V	and	VI	 in	the	presence	(B)	or	 in	
the	 absence	 (C)	 of	 transfecting	 agent	 Lipofectamine	 2000	 in	
HEK-293	 cells	 previously	 transfected	 with	 Renilla	 and	 Firefly	
luciferase	 plasmids.	 Untreated	 cells:	 cells	 treated	 with	
plasmids	alone.	
	
	 Importantly,	 WB	 analysis	 of	 cells	 treated	 with	 peptide	
vehicles	alone	confirmed	that	the	inhibitory	effect	(Fig.	4)	was	
exclusively	 induced	 by	 the	 siRNA-peptide	 conjugates,	 as	
peptide	 treatment	 did	 not	 cause	 any	 decrease	 in	 the	 HER2	
protein	 level	 (Fig.	 S9).	 Furthermore,	 cell	 viability	 assays	 ruled	
out	any	toxicity	from	the	peptides	themselves	(Fig.	S10).	
	 In	 summary,	we	have	presented	here	a	mild	 and	efficient	
methodology	 for	 conjugating	 peptides	 to	 RNA	 via	 click	
chemistry	 in	excellent	yield	and	purity.	This	approach	enables	
the	 efficient	 construction	 of	 siRNAs	 modified	 with	 receptor-
binding	peptides	of	different	size	and	complexity	at	the	5'-end	
of	the	sense	siRNA	strand.	By	using	this	approach	we	have	also	
been	able	to	induce	selectively	gene	silencing	in	HER2+	cancer	
cell	 lines	 with	 novel	 siRNA-peptide	 conjugates,	 making	
particularly	 appealing	 the	use	of	 Tat-AHNP	 targeting	 peptide.	
Although	750	nM-1	μM	doses	are	needed,	our	approach	offers	
the	 ability	 to	 selectively	 deliver	 the	 siRNA	 inside	 tumor	 cells	
overexpressing	 specific	 receptors,	 which	 would	 minimize	
undesired	effects	in	healthy	cells.	
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